Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis – Overview
Familial Adenomatous Polyposis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis – Companies Involved in Therapeutics Development
ADT Pharmaceuticals Inc
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Eloxx Pharmaceuticals Inc
Emtora Biosciences
FunPep Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Recursion Pharmaceuticals Inc
SanaRx Biotherapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
TherapyX Inc
Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis – Drug Profiles
(eflornithine hydrochloride + sulindac) – Drug Profile
Product Description
Mechanism Of Action
History of Events
CLXONC-575 – Drug Profile
Product Description
Mechanism Of Action
FAPXIL SR – Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
guselkumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
icosapent ethyl – Drug Profile
Product Description
Mechanism Of Action
History of Events
interleukin-10 SR – Drug Profile
Product Description
Mechanism Of Action
History of Events
lorpucitinib – Drug Profile
Product Description
Mechanism Of Action
History of Events
magnesium lysinate bis eicosapentaenoate – Drug Profile
Product Description
Mechanism Of Action
History of Events
ombipepimut-s – Drug Profile
Product Description
Mechanism Of Action
History of Events
pyrvinium pamoate – Drug Profile
Product Description
Mechanism Of Action
History of Events
REC-4881 – Drug Profile
Product Description
Mechanism Of Action
History of Events
SB-201 – Drug Profile
Product Description
Mechanism Of Action
SHR-1020 – Drug Profile
Product Description
Mechanism Of Action
sirolimus – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PDE10 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic peptide for Familial Adenomatous Polyposis – Drug Profile
Product Description
Mechanism Of Action
History of Events
ZKN-013 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Familial Adenomatous Polyposis – Dormant Projects
Familial Adenomatous Polyposis – Discontinued Products
Familial Adenomatous Polyposis – Product Development Milestones
Featured News & Press Releases
Oct 12, 2021: Flynpovi: Withdrawal of the marketing authorisation application
Sep 29, 2021: Recursion is granted orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis
Jul 23, 2021: Cancer Prevention Pharmaceuticals has requested a re-examination of EMA’s June 2021 opinion on Flynpovi
Jun 25, 2021: CHMP adopted a negative opinion on the marketing authorisation application for Flynpovi
Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis
Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis
Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis
Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19
Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards $2,073,687 SBIR fasttrack grant to Therapyx
Aug 26, 2019: Emtora Biosciences awarded $3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis
Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA
Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference
May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis
Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis
Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development for Familial Adenomatous Polyposis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, 2022
Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, 2022
Familial Adenomatous Polyposis - Pipeline by KD Pharma Group SA, 2022
Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by SanaRx Biotherapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, 2022
Familial Adenomatous Polyposis - Dormant Projects, 2022
Familial Adenomatous Polyposis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Familial Adenomatous Polyposis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/